Adverse events associated with benznidazole treatment for Chagas disease in children and adults
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16214 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Cintia Valeria Cruz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Parasitología y Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Ricardo …. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Trypanocidal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, This work was partially funded by Wellcome Trust.
Themen: Patientensicherheit, Kinderkrankenpflege
Abstract (Originalsprache)
Aims
Chagas disease (ChD) affects approximately 7 million people in Latin America, with benznidazole being the most commonly used treatment.
Methods
Data from a retrospective cohort study in Argentina, covering January 1980 to July 2019, was reanalysed to identify and characterize benznidazole‐related adverse drug reactions (ADRs).
Results
The study included 518 patients: 449 children and 69 adults (median age in children: 4 years; adults: 25 years; age ranges: 1 month–17.75 years and 18–59 years, respectively). The median benznidazole doses received were 6.6 mg/kg/day for at least 60 days in children and 5.6 mg/kg/day for a median of 31 days in adults. Overall, 29.34% (152/518) of patients developed benznidazole‐related ADRs, with an incidence of 25.83% (116/449) in children and 52.17% (36/69) in adults (odds ratio [OR] = 0.32, 95% confidence interval [CI] = 0.19–0.54, P < .001). The incidence rate was 177 cases per 1000 person‐years (95% CI = 145–214) in children and 537 per 1000 person‐years (95% CI = 360–771) in adults. There were 240 ADRs identified, primarily mild to moderate. Severe ADRs occurred in 1.11% (5/449) of children and 1.45% (1/69) of adults. The skin was the most affected system. A total of 10.23% (53/518) of patients discontinued treatment. More adults than children discontinued treatment (OR = 3.36, 95% CI = 1.7–6.4, P < .001).
Conclusions
Although 29.34% of patients experienced ADRs, most were mild to moderate, indicating a manageable safety profile for benznidazole. While optimized dosing schedules and new drugs are needed, avoiding benznidazole solely due to safety concerns is not justified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Parasitología y Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
- Mahidol Oxford Research Unit (MORU), Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
ORCID-Profile: Cintia Valeria Cruz, Facundo Garcia-Bournissen, Jaime Altcheh
Förderung
- Wellcome Trust
- This work was partially funded by Wellcome Trust
Zitieren
APA
Cruz, C. V., Rabinovich, A., Moscatelli, G., Moroni, S., González, N., Garcia-Bournissen, F., Ballering, G., Freilij, H., & Altcheh, J. (2024). Adverse events associated with benznidazole treatment for Chagas disease in children and adults. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16214
Vancouver
Cruz CV, Rabinovich A, Moscatelli G, Moroni S, González N, Garcia-Bournissen F, et al. Adverse events associated with benznidazole treatment for Chagas disease in children and adults. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16214
BibTeX
@article{Cruz2024,
author = {Cruz, Cintia Valeria and Rabinovich, Andres and Moscatelli, Guillermo and Moroni, Samanta and González, Nicolas and Garcia-Bournissen, Facundo and Ballering, Griselda and Freilij, Hector and Altcheh, Jaime},
title = {Adverse events associated with benznidazole treatment for Chagas disease in children and adults},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16214}
}
EUVIMED